{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:54:01Z","timestamp":1793840041828,"version":"4.6.1"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immune checkpoint therapy\n                    <jats:italic>via<\/jats:italic>\n                    PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment has now entered the age of immunotherapy. Although cancer immunotherapy has shown remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss the basic classification, research progress, and limitations of cancer immunotherapy. Besides, by combining cancer immunotherapy resistance mechanism with analysis of combination therapy, we give our insights into the development of new anticancer immunotherapy strategies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.961805","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T03:58:48Z","timestamp":1665460728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":201,"title":["Clinical cancer immunotherapy: Current progress and prospects"],"prefix":"10.3389","volume":"13","author":[{"given":"Chenglong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002459","article-title":"Systematic review of combinations of targeted or immunotherapy in advanced solid tumors","volume":"9","author":"Tan","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: From enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12332","article-title":"Fc receptor inside-out signaling and possible impact on antibody therapy","volume":"268","author":"Brandsma","year":"2015","journal-title":"Immunol Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00481","article-title":"Targeting the antibody checkpoints to enhance cancer immunotherapy-focus on Fc\u03b3RIIB","volume":"10","author":"Teige","year":"2019","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2009.10.011","article-title":"Optimization of fc-mediated effector functions of monoclonal antibodies","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan","year":"2010","journal-title":"MAbs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000337577","article-title":"Rituximab and cytokine release syndrome","volume":"5","author":"Kulkarni","year":"2012","journal-title":"Case Rep Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1752-1947-7-280","article-title":"Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large b-cell lymphoma: a case report and review of the literature","volume":"7","author":"Makino","year":"2013","journal-title":"J Med Case Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.12.002","article-title":"Bispecific antibodies for cancer therapy: A review","volume":"185","author":"Krishnamurthy","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2016.11.004","article-title":"The state-of-play and future of antibody therapeutics","volume":"122","author":"Elgundi","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.canlet.2021.04.021","article-title":"Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy","volume":"511","author":"Wei","year":"2021","journal-title":"Cancer Lett"},{"key":"B17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yonc.2012.07.009","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: a promising anticancer therapy","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discovery Today"},{"key":"B23","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00311","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"111876","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in PD-1\/PD-L1 pathway inhibitors: From biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0481","article-title":"Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma","volume":"76","author":"Dawkins","year":"2016","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24283","article-title":"Analysis of response rate with ANTI PD1\/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials","volume":"9","author":"Carretero-Gonz\u00e1lez","year":"2018","journal-title":"Oncotarget"},{"key":"B35","first-page":"WO2015033301","article-title":"1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE DERIVATIVES AS IMMUNOMODULATORS","author":"Sasikumar","year":"2015","journal-title":"Aurigene discovery technologies limited"},{"key":"B36","first-page":"WO2015033299","article-title":"1,2,4-OXADIAZOLE DERIVATIVES AS IMMUNOMODULATORS","author":"Sasikumar","year":"2015","journal-title":"Aurigene discovery technologies limited"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41467-021-21410-1","article-title":"Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1","volume":"12","author":"Park","year":"2021","journal-title":"Nat Commun"},{"key":"B38","first-page":"US2011318373","article-title":"Immunosuppression modulating compounds","author":"Sasikumar","year":"2011","journal-title":"Aurigene discovery technologies limited"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0737","article-title":"A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy, mol","volume":"18","author":"Sasikumar","year":"2019","journal-title":"Cancer Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2012-2850","article-title":"Abstract 2850: Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway","volume":"72","author":"Sasikumar","year":"2012","journal-title":"Cancer Res"},{"key":"B41","first-page":"WO2018044963","article-title":"Biaryl compounds useful as immunomodulators","author":"Yeung","year":"2018","journal-title":"Bristol-Myers Squibb company"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15457","article-title":"Discovery of a novel, potent and selective small-molecule inhibitor of PD-1\/PD-L1 interaction with robust in vivo anti-tumour efficacy","volume":"178","author":"Liu","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","article-title":"Trial watch: IDO inhibitors in cancer therapy","volume":"9","author":"Le Naour","year":"2020","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.11.007","article-title":"Targeting the IDO1\/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities","volume":"39","author":"Cheong","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"B47","doi-asserted-by":"publisher","first-page":"Of5","DOI":"10.1158\/2159-8290.CD-ND2018-007","article-title":"Companies scaling back IDO1 inhibitor trials","volume":"8","year":"2018","journal-title":"Cancer Discovery"},{"key":"B48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/bs.ircmb.2017.07.004","article-title":"Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer","volume":"336","author":"Prendergast","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"283ra252","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"113113","DOI":"10.1016\/j.ejmech.2020.113113","article-title":"STING, a promising target for small molecular immune modulator: A review","volume":"211","author":"Liu","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"CCR-22-0612","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase 1a\/b, open-label, multicenter study of AZD4635 (an adenosine 2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"31","author":"Lim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2742","article-title":"Phase I study of taminadenant (PBF509\/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab (PDR001), in patients with advanced non-small cell lung cancer","volume":"28","author":"Chiappori","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1638883","article-title":"Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial","volume":"31","author":"Jia","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-01058-2","article-title":"A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy","volume":"39","author":"Choueiri","year":"2021","journal-title":"Invest New Drugs"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI88959","article-title":"Driving an improved CAR for cancer immunotherapy","volume":"126","author":"Huang","year":"2016","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.15218","article-title":"FDA Approval of tisagenlecleucel: Promise and complexities of a $475 000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"Jama"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2159-8290.CD-NB2017-155","article-title":"FDA Approves second CAR T-cell therapy","volume":"8","year":"2018","journal-title":"Cancer Discovery"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J Control Release"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.74","article-title":"The global landscape of cancer cell therapy","volume":"17","author":"Tang","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory b cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-019-0705-x","article-title":"Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia","volume":"12","author":"Zhao","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn8264","article-title":"Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors","volume":"8","author":"Grosskopf","year":"2022","journal-title":"Sci Adv"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-016-0367-1","article-title":"T-Cell receptor-engineered T cells for cancer treatment: current status and future directions","volume":"9","author":"Ping","year":"2018","journal-title":"Protein Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: Current strategies","volume":"13","author":"Shafer","year":"2022","journal-title":"Challenges Prospects Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. a preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181f05b91","article-title":"Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL","volume":"33","author":"Goff","year":"2010","journal-title":"J Immunother"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0962","article-title":"A burned-out CD8(+) T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy","volume":"11","author":"Sanmamed","year":"2021","journal-title":"Cancer Discovery"},{"key":"B75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-016-0164-7","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors","volume":"4","author":"Hall","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.033","article-title":"CAR-NK for tumor immunotherapy: Clinical transformation and future prospects","volume":"472","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2018.11.015","article-title":"Natural killer cell-based immunotherapy for cancer: Advances and prospects","volume":"5","author":"Hu","year":"2019","journal-title":"Engineering"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.12.012","article-title":"High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18","volume":"534","author":"Liu","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120944","article-title":"Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors","volume":"209","author":"Ni","year":"2012","journal-title":"J Exp Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02103","article-title":"Oncolytic viruses partner With T-cell therapy for solid tumor treatment","volume":"9","author":"Rosewell Shaw","year":"2018","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2020.10.023","article-title":"Clinical CAR-T cell and oncolytic virotherapy for cancer treatment","volume-title":"Mol Ther","author":"Watanabe","year":"2021"},{"key":"B90","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/OV.S36623","article-title":"Cell carriers for oncolytic viruses: current challenges and future directions","volume":"2","author":"Roy","year":"2013","journal-title":"Oncolytic Virother"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.cell.2019.10.038","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30571","article-title":"The antiresection activity of the X protein encoded by hepatitis virus b","volume":"69","author":"Ren","year":"2019","journal-title":"Hepatology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99538","article-title":"Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors","volume":"129","author":"Chen","year":"2019","journal-title":"J Clin Invest"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1552-9","article-title":"Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients","volume":"63","author":"Herrera","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Cancer immunotherapy Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw030","article-title":"Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation","volume":"28","author":"Yaguchi","year":"2016","journal-title":"Int Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40257-018-0389-y","article-title":"Mechanisms of resistance to immune checkpoint blockade","volume":"20","author":"Liu","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2017.07.002","article-title":"Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects","volume":"32","author":"Jia","year":"2017","journal-title":"Drug Resist Update"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0400-7","article-title":"Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression","volume":"20","author":"Hu","year":"2019","journal-title":"Nat Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B104","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B105","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","article-title":"BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discovery"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4219","article-title":"Genome-wide CRISPR screens reveal a wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors","volume":"23","author":"Steinhart","year":"2017","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","first-page":"E7697","DOI":"10.1073\/pnas.1710366114","article-title":"Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC","volume":"114","author":"Satoh","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B112","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","article-title":"Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy","volume":"27","author":"Cascone","year":"2018","journal-title":"Cell Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2003.01730.x","article-title":"Paradoxical effects of interleukin-10 on the maturation of murine myeloid dendritic cells","volume":"110","author":"Commeren","year":"2003","journal-title":"Immunology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"237ra267","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"J Exp Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050930","article-title":"B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma","volume":"203","author":"Kryczek","year":"2006","journal-title":"J Exp Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.106","article-title":"Human PBMC-transferred murine MHC class I\/II-deficient NOG mice enable long-term evaluation of human immune responses","volume":"15","author":"Yaguchi","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2018-065","article-title":"Explaining resistance to CAR T cells","volume":"8","year":"2018","journal-title":"Cancer Discovery"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","author":"Majzner","year":"2017","journal-title":"Cancer Cell"},{"key":"B127","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1509660","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bulcan.2018.01.018","article-title":"Blocking Tim-3 or\/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma","volume":"105","author":"Liu","year":"2018","journal-title":"Bull Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0671-1","article-title":"Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model","volume":"58","author":"Banissi","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/s41467-018-04605-x","article-title":"Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap","volume":"9","author":"Song","year":"2018","journal-title":"Nat Commun"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B143","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-014-0037-x","article-title":"Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes","volume":"2","author":"Pilones","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B148","article-title":"Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs","volume":"6","author":"Du Four","year":"2016","journal-title":"Am J Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0385","article-title":"Combined anti-VEGF and anti-CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"106227","DOI":"10.1016\/j.intimp.2020.106227","article-title":"Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy","volume":"81","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/CJI.0000000000000301","article-title":"CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models","volume":"43","author":"Li","year":"2020","journal-title":"J\u00a0Immunother"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12967-016-0791-2","article-title":"Melanoma and immunotherapy bridge 2015 : Naples, italy. 1-5 December 2015","volume":"14","author":"Nanda","year":"2016","journal-title":"J\u00a0Transl Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.05.015","article-title":"A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy","volume":"19","author":"Takeda","year":"2017","journal-title":"Cell Rep"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0049","article-title":"Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity","volume":"5","author":"Ager","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B157","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","first-page":"112698","DOI":"10.1016\/j.ejmech.2020.112698","article-title":"PROTACs: New method to degrade transcription regulating proteins","volume":"207","author":"Hu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.02.010","article-title":"Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1","volume":"10","author":"Hu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182829747","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.60","article-title":"Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor","volume":"23","author":"van den Berg","year":"2015","journal-title":"Mol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.961805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T03:58:56Z","timestamp":1665460736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.961805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":161,"alternative-id":["10.3389\/fimmu.2022.961805"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.961805","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"article-number":"961805"}}